companies · US EditionLive
argenx
TLDR
argenx is a NASDAQ-listed Belgian biotech company headquartered in Ghent, developing antibody-based therapeutics for severe autoimmune diseases.
Overview
Founded in 2008 and listed on NASDAQ and Euronext Brussels, argenx is one of Belgium's most successful biotech companies by market capitalization. The company focuses on developing treatments for severe autoimmune diseases using its proprietary antibody technology platform, SIMPLE Antibody. Its lead product, efgartigimod, is approved in multiple markets for myasthenia gravis and several other indications.
See also
FounderTim Van Hauwermeiren
FounderHans de Haard
FounderTorsten Dreier
LocationGhent
RelatedBrussels
RelatedAgomAb Therapeutics
RelatedGalapagos
RelatedUCB
RelatedOnno van de Stolpe
RelatedTim Knotnerus
RelatedAgomAb Therapeutics IPO 2026
RelatedAnnie Vereecken
Open positions
All 12 →- Senior Scientist CMCResearch, Analyst, and Information Technology · Ghent, Flemish Region, Belgium
- Human Factors ExpertInformation Technology · Ghent, Flemish Region, Belgium
- Principal Scientist BioanalyticsEducation and Training · Ghent, Flemish Region, Belgium
- Toxicologist late stage clinical development and established AssetsResearch, Analyst, and Information Technology · Ghent, Flemish Region, Belgium · remote
- Biomarker Biostatistics LeadOther · Ghent, Flemish Region, Belgium · remote
- Director, Regulatory CMC Device LeaderLegal · Ghent, Flemish Region, Belgium
- Senior Translational ScientistResearch, Analyst, and Information Technology · Ghent, Flemish Region, Belgium
- Supply Chain ManagerManagement and Manufacturing · Ghent, Flemish Region, Belgium
- Biostatistics Director - Indication LeadResearch, Analyst, and Information Technology · Belgium · remote
- Internal Event Leader - Ghent CampusManagement and Manufacturing · Ghent, Flemish Region, Belgium
- Clinical Operations Development LeadManagement and Manufacturing · Ghent, Flemish Region, Belgium · remote
- Finance Business Partner R&DFinance and Sales · Ghent, Flemish Region, Belgium · hybrid
Recent mentions
- Beursupdate: Bel20 bouwt winst uitKnack · 22 May 2026
- Our time at #Autoimmunity2026 reinforced how complex, yet interconnected, autoimmune diseases truly are. Researchers and clinicians presented emerging insights into immune pathways and disease mechaniLinkedIn · 21 May 2026
- CIDP doesn't always look the same – making it hard to recognize. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease that affects strength, sensation, and mobility, mLinkedIn · 14 May 2026
- Today, the U.S. FDA approved an expanded indication for the treatment of all adults living with generalized myasthenia gravis (gMG). “Today’s approval means that all adult gMG patients, regardless of LinkedIn · 08 May 2026
- Q1 marked strong progress toward Vision 2030 — our long-term ambition to reach 50,000 patients by 2030. This momentum was driven by continued advancements in myasthenia gravis (MG) and chronic inflammLinkedIn · 07 May 2026
- “At argenx, everything starts with one question: how do we create the most value for patients?” – Karen Massey As Karen officially steps into the role of Chief Executive Officer, this focus continues LinkedIn · 06 May 2026
- Scientific progress doesn’t happen by chance. It’s driven by our entrepreneurial mindset. Recent momentum across MG subtypes, broader engagement across the CIDP community, and continued advancement wiLinkedIn · 28 Apr 2026
- Beursupdate: weinig stijgers in BrusselKnack · 24 Apr 2026
Filed under